Preliminary results from a phase I, first-in-human study of DS-9606a, a claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6

被引：2
|
作者：
Patel, M. R. [1 ,2 ]
Hamilton, E. P. [2 ]
Piha-Paul, S. A. [3 ]
Henry, J. [4 ]
Banerji, U. [6 ]
Al Hallak, M. N. [5 ,7 ]
Okada, H. [8 ]
Qian, M. [9 ]
Zhang, X. [10 ]
Said, N. [11 ]
Chatikhine, V. [12 ]
Fontana, E. [13 ]
机构：
[1] Florida Canc Specialists, Drug Dev Unit, Sarasota, FL USA
[2] Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA
[4] HealthOne, Sarah Cannon Res Inst, Drug Dev Unit, Denver, CO USA
[5] Inst Canc Res, Drug Dev Unit, London, England
[6] Royal Marsden Hosp, London, England
[7] Karmanos Canc Inst, Dept Oncol, Detroit, MI USA
[8] Daiichi Sankyo Inc, Clin Sci, Basking Ridge, NJ USA
[9] Daiichi Sankyo Inc, Biostat & Data Management, Basking Ridge, NJ USA
[10] Daiichi Sankyo Inc, Quantitat Clin Pharmacol, Basking Ridge, NJ USA
[11] Daiichi Sankyo Inc, Clin Safety & Pharmacovigilance, Basking Ridge, NJ USA
[12] Daiichi Sankyo Inc, Early Clin Dev, Basking Ridge, NJ USA
[13] Sarah Cannon Res Inst SCRI UK, Drug Dev, London, England
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.677
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
610O
引用
收藏
页码：S488 / S489
页数：2
相关论文
共 50 条
  • [21] First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors
    Angevin, E.
    Kelly, K.
    Heist, R.
    Morgensztern, D.
    Weekes, C.
    Bauer, T. M.
    Ramanathan, R. K.
    Nemunaitis, J.
    Fan, X.
    Olyaie, O.
    Parikh, A.
    Reilly, E.
    Afar, D.
    Naumovski, L.
    Strickler, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] First-in-human phase I/IIa clinical trial of ZV0203, a novel pertuzumab-based antibody-drug conjugate (ADC), in patients (pts) with Her2 positive advanced solid
    Lin, F.
    Huang, Y.
    Huang, Y.
    Lu, Y.
    Rao, X.
    Wang, X.
    Wang, F.
    Huang, X.
    ANNALS OF ONCOLOGY, 2024, 35 : S354 - S355
  • [23] A phase I study evaluating DLYE5953A, an antibody-drug conjugate targeting the tumor-associated antigen lymphocyte antigen 6 complex locus E (Ly6E), in patients (Pts) with solid tumors
    Modi, S.
    Eder, J. P.
    Lorusso, P.
    Weekes, C.
    Chandarlapaty, S.
    Tolaney, S. M.
    McLaughlin, J.
    Camidge, D. R.
    Chang, C-W.
    Nazzal, D.
    Chen, S-C.
    Schuth, E.
    Brunstein, F.
    Darbonne, W.
    Flanagan, W.
    Ungewickell, A.
    Shapiro, G.
    ANNALS OF ONCOLOGY, 2016, 27
  • [24] BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study
    Zhang, Li
    Ma, Yuxiang
    Zhao, Yuanyuan
    Fang, Wenfeng
    Zhao, Hongyun
    Huang, Yan
    Yang, Yunpeng
    Chen, Likun
    Hou, Xue
    Zou, Wen
    Ding, Muran
    Yu, Jing
    Zhang, Suoyu
    Wang, Junxian
    Xiao, Sa
    Wang, Hongwei
    Zhu, Hai
    Olivo, Martin Sebastian
    Zhu, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced gynecological cancers (Gynecol C): Results from a phase I study
    Shu, J.
    Zhu, T.
    Huang, Y.
    Xu, Q.
    Guo, R.
    Liu, H.
    Zhao, H.
    Zhu, L.
    Wang, X.
    Xu, X.
    Cheng, W.
    Tang, J.
    Zhu, Q.
    Chen, X.
    An, R.
    Gao, J.
    Li, G.
    Zhang, Z.
    Zhou, H.
    Zhou, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S551 - S551
  • [26] A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870).
    Gomez-Roca, Carlos Alberto
    Boni, Valentina
    Moreno, Victor
    Morris, John Charles
    Delord, Jean-Pierre
    Calvo, Emiliano
    Papadopoulos, Kyriakos P.
    Rixe, Olivier
    Cohen, Patrick
    Tellier, Alexia
    Ziti-Ljajic, Samira
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] APEX-01: First-in-human phase I/II study of ARX517 an antiprostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castrationresistant prostate cancer (mCRPC)
    Shen, J.
    Pachynski, R.
    Nordquist, L. T.
    Adra, N.
    Bilen, M. A.
    Aggarwal, R.
    Reichert, Z.
    Schweizer, M.
    Iravani, A.
    Aung, S.
    Hessel, C.
    Tagawa, S. T.
    ANNALS OF ONCOLOGY, 2023, 34 : S974 - S975
  • [28] IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): Results from a phase I study
    Lemech, C.
    Sun, Y.
    Nagrial, A.
    Wu, X.
    Morris, M.
    Ning, F.
    Yang, J.
    Pan, Y.
    Cai, J.
    Lu, P.
    Zhang, T.
    Qiu, F.
    Hu, C.
    Zhang, M.
    Liu, Z.
    Han, G.
    Nie, J.
    Teng, C.
    Zhou, H.
    Day, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S360 - S360
  • [29] ABBV-400, a c-Met proteinetargeting antibody-drug conjugate (ADC), in patients (pts) with advanced gastric/gastroesophageal junction adenocarcinoma (GEA): Results from a phase I study
    Strickler, J. H.
    Raimbourg, J.
    Ghiringhelli, F.
    Cohen, J. E.
    Kitagawa, C.
    Sharma, M. R.
    Lee, K. H.
    De Miguel, M.
    Hunter, Z. N.
    Burns, M.
    Li, R. R.
    Rudraganguly, N.
    de Almeida, C. Biesdorf
    Freise, K. J.
    Blaney, M. E.
    Morrison-Thiele, G.
    Aristide, M. R. Neagu
    Kuboki, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S895 - S896
  • [30] Preliminary dose escalation results from a phase I/II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors.
    Powderly, John D.
    Jang, Sekwon
    Lohr, Joanna
    Spira, Alexander, I
    Bohac, Gerry C.
    Sharma, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345